IOVANCE ALERT: Bragar Eagel & Squire, P.C. Announces that a Class Action Lawsuit Has Been Filed Against Iovance Biotherapeutics, Inc. and Encourages Investors to Contact the Firm

Core Viewpoint - A class action lawsuit has been filed against Iovance Biotherapeutics, Inc. for allegedly providing misleading statements about its growth potential and failing to capitalize on demand for its treatments during the class period from May 9, 2024, to May 8, 2025 [1][3]. Company Performance - Iovance announced its financial results for Q2 2024 on July 25, 2024, and reduced its revenue guidance for the full fiscal year 2024 due to several factors, including maintenance that reduced capacity, lower-than-expected Proleukin sales, and the variable pace of treatment initiation [4]. - Following the announcement of reduced guidance, Iovance's stock price plummeted from $3.17 per share on May 8, 2025, to$1.75 per share on May 9, 2025, marking a decline of approximately 44.8% in one day [4]. Legal Proceedings - The lawsuit is on behalf of all individuals and entities that purchased Iovance securities during the specified class period, with a deadline of July 14, 2025, for investors to apply as lead plaintiffs [1]. - The complaint alleges that the company concealed material adverse facts regarding its ability to meet demand for its treatments [3]. Investor Information - Investors who suffered losses or have questions regarding the lawsuit can contact the law firm Bragar Eagel & Squire, P.C. for more information [5].